<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39327031</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1460-2091</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Sep</Month><Day>27</Day></PubDate></JournalIssue><Title>The Journal of antimicrobial chemotherapy</Title><ISOAbbreviation>J Antimicrob Chemother</ISOAbbreviation></Journal><ArticleTitle>Outcomes of patients hospitalized in ward settings for COVID-19 pneumonia with or without early empirical antibiotics.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">dkae350</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/jac/dkae350</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">During the first pandemic of COVID-19, early empirical antibiotic use rates for pneumonia varied widely. The benefit remains hypothetical.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We assessed the benefit of empirical antibiotic use at admission in patients hospitalized with COVID-19 pneumonia. We enrolled all adults admitted from 1 March to 30 April 2020 with symptoms for ≤14 days, a positive nasopharyngeal PCR or a highly suggestive CT scan. The primary outcome was mortality at Day 28. The secondary outcomes were transfer to the ICU, mechanical ventilation and length of hospital stay. To handle confounding-by-indication bias, we used a propensity score analysis, expressing the outcomes in the original and overlap weighted populations.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among 616 analysed patients, 402 (65%) received antibiotics. At Day 28, 102 patients (17%) had died, 90 (15%) had been transferred to the ICU and 24 (4%) had required mechanical ventilation. Mortality in patients who received antibiotics was higher before but not after weighting (OR 2.7, 95% CI 1.5-5.0, P &lt; 0.001 and OR 1.4, 95% CI 0.8-2.5, P = 0.28, respectively. Antibiotic use had no benefit on: transfer to ICU before and after weighting (OR 1.3, 95% CI 0.8-2.3, P = 0.30 and OR 1.1, 95% CI 0.6-1.9, P = 0.78, respectively); mechanical ventilation before and after weighting (OR 0.5, 95% CI 0.2-1.1, P = 0.079 and OR 0.75, 95% CI 0.3-2.0, P = 0.55, respectively); and length of hospital stay before and after weighting (mean difference -0.02 ± 0.5 days, P = 0.97 and mean difference 0.54 ± 0.75 days, P = 0.48, respectively).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">We did not find any benefit of antibiotic use in patients hospitalized with COVID-19 pneumonia.</AbstractText><CopyrightInformation>© The Author(s) 2024. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kopp-Derouet</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Infectious Diseases Department, Hôpitaux Saint-Louis/Lariboisière, APHP, Hôpital Lariboisière, 2, rue Ambroise Paré, 75475, Paris Cedex 10, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Université de Paris Cité, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Infectious Diseases and Internal Medicine Department, GH SIF, Melun, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>DYNAMIC Unit, UPEC, Créteil, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Diamantis</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Infectious Diseases and Internal Medicine Department, GH SIF, Melun, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>DYNAMIC Unit, UPEC, Créteil, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chevret</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Biostatistics and Medical Informatics, Hôpitaux Saint-Louis/Lariboisière, APHP, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Université de Paris Cité, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tazi</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Respiratory Diseases, Hôpitaux Saint-Louis/Lariboisière, APHP, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Université de Paris Cité, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burlacu</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Hôpitaux Saint-Louis/Lariboisière, APHP, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Université de Paris Cité, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kevorkian</LastName><ForeName>J P</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Department of Endocrinology, Hôpitaux Saint-Louis/Lariboisière, APHP, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Université de Paris Cité, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Julla</LastName><ForeName>J B</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>Department of Endocrinology, Hôpitaux Saint-Louis/Lariboisière, APHP, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Université de Paris Cité, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Molina</LastName><ForeName>J M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Infectious Diseases Department, Hôpitaux Saint-Louis/Lariboisière, APHP, Hôpital Lariboisière, 2, rue Ambroise Paré, 75475, Paris Cedex 10, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Université de Paris Cité, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sellier</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Infectious Diseases Department, Hôpitaux Saint-Louis/Lariboisière, APHP, Hôpital Lariboisière, 2, rue Ambroise Paré, 75475, Paris Cedex 10, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Université de Paris Cité, Paris, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Antimicrob Chemother</MedlineTA><NlmUniqueID>7513617</NlmUniqueID><ISSNLinking>0305-7453</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>27</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>27</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>26</Day><Hour>21</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39327031</ArticleId><ArticleId IdType="doi">10.1093/jac/dkae350</ArticleId><ArticleId IdType="pii">7778290</ArticleId></ArticleIdList></PubmedData></PubmedArticle>